Ascendis Pharma A/S (NASDAQ:ASND) Price Target Cut to $178.00 by Analysts at Citigroup

Ascendis Pharma A/S (NASDAQ:ASND) had its price target trimmed by Citigroup from $193.00 to $178.00 in a research report released on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also recently issued reports on ASND. StockNews.com cut shares of Ascendis Pharma A/S from a hold rating to a sell rating in a report on Tuesday, August 13th. Cantor Fitzgerald dropped their price objective on Ascendis Pharma A/S from $173.00 to $170.00 and set an overweight rating on the stock in a research note on Wednesday. Jefferies Financial Group lifted their target price on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a buy rating in a research note on Tuesday, August 13th. Oppenheimer upgraded Ascendis Pharma A/S from a market perform rating to an outperform rating and set a $180.00 price target on the stock in a research note on Thursday. Finally, Stifel Nicolaus began coverage on shares of Ascendis Pharma A/S in a report on Friday, May 31st. They issued a buy rating and a $200.00 price objective on the stock. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $187.08.

Ascendis Pharma A/S Trading Up 0.1 %

Shares of ASND opened at $119.15 on Wednesday. The company’s fifty day simple moving average is $134.38 and its 200 day simple moving average is $138.20. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00. The company has a market cap of $6.94 billion, a price-to-earnings ratio of -12.40 and a beta of 0.63.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors have recently bought and sold shares of ASND. Vestal Point Capital LP acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at about $78,719,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after buying an additional 336,976 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Ascendis Pharma A/S by 20.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock worth $191,346,000 after buying an additional 254,749 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Ascendis Pharma A/S by 1,461.1% during the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after buying an additional 234,446 shares during the last quarter. Finally, Avoro Capital Advisors LLC boosted its stake in Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after buying an additional 229,995 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.